Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Sales of AbbVie's Humira are plummeting as the once-top-selling drug fights ...

(Reuters) -AbbVie expects a drop in sales volumes of its blockbuster arthritis drug Humira to deepen after recent changes by U.S. pharmacy benefit managers and as patients shift to other drugs. Its ...

Shares of AbbVie (NYSE:ABBV) were down 6% in afternoon trading Friday in the wake of the drugmaker's Q1 earnings report and news that Cigna (CI) plans to offer a biosimilar of AbbVie’s top-selling ...

Please provide your email address to receive an email when new articles are posted on . AbbVie reported a worldwide net revenue of $12.31 billion and a 0.7% increase in its first quarter. Global net ...

AbbVie is a leading pharmaceutical company with a diverse portfolio of products and strong revenue growth. The company has a solid track record of increasing dividends and offers an attractive current ...

AbbVie Inc’s (NYSE:ABBV) top-selling arthritis drug, Humira, has managed to retain over 80% of its patients even after facing nine lower-priced rivals in the U.S. over the past year, Reuters reports.

Investors pummeled AbbVieABBV stock Wednesday after the company delivered a fourth-quarter sales beat that came largely on the back of still-declining Humira sales. Once key to AbbVie's top line, ...